ASLAN Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
SAN MATEO, Calif. and SINGAPORE, April 28, 2023 (GLOBE NEWSWIRE) — ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced financial results for the first quarter ended March 31, 2023, and provided an update on recent corporate activities.
Related news for (ASLN)
- ASLAN Pharmaceuticals Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
- ASLAN Pharmaceuticals Announces $20M Private Placement Led by BVF Partners L.P. With the Potential to Receive Up to an Additional $80M
- ASLAN Pharmaceuticals Announces $20M Private Placement Led by BVF Partners L.P. With the Potential to Receive Up to an Additional $80M
- ASLAN Pharmaceuticals Announces Completion of Recruitment in Phase 2b TREK-AD Study of Eblasakimab in Atopic Dermatitis Patients